Cwm LLC Purchases 6,335 Shares of Medifast Inc $MED

Cwm LLC raised its position in Medifast Inc (NYSE:MED) by 564.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,457 shares of the specialty retailer’s stock after acquiring an additional 6,335 shares during the quarter. Cwm LLC owned approximately 0.07% of Medifast worth $105,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Strs Ohio bought a new position in Medifast in the first quarter valued at about $78,000. Russell Investments Group Ltd. increased its position in Medifast by 114.1% in the first quarter. Russell Investments Group Ltd. now owns 19,514 shares of the specialty retailer’s stock worth $267,000 after buying an additional 10,401 shares in the last quarter. Benjamin Edwards Inc. increased its position in Medifast by 75.0% in the first quarter. Benjamin Edwards Inc. now owns 24,419 shares of the specialty retailer’s stock worth $329,000 after buying an additional 10,469 shares in the last quarter. Amundi increased its position in Medifast by 43.5% in the first quarter. Amundi now owns 30,439 shares of the specialty retailer’s stock worth $398,000 after buying an additional 9,224 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Medifast in the first quarter worth about $407,000. Institutional investors own 95.51% of the company’s stock.

Medifast Trading Down 0.7%

NYSE:MED opened at $12.06 on Friday. Medifast Inc has a 12-month low of $11.57 and a 12-month high of $21.98. The stock has a 50-day moving average price of $13.57 and a 200 day moving average price of $13.53. The stock has a market capitalization of $132.48 million, a P/E ratio of 37.67 and a beta of 0.85.

Medifast (NYSE:MED) last released its earnings results on Monday, August 4th. The specialty retailer reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.26. Medifast had a return on equity of 2.00% and a net margin of 0.76%.The firm had revenue of $105.56 million during the quarter, compared to analysts’ expectations of $96.10 million. Medifast has set its Q3 2025 guidance at -0.600-0.00 EPS. On average, research analysts predict that Medifast Inc will post 0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Medifast in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $16.50.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.